New strategies in the treatment of graft-versus-host disease

被引：12

作者：

Basara, N ^{[1
]}

Blau, IW ^{[1
]}

Willenbacher, W ^{[1
]}

Kiehl, MG ^{[1
]}

Fauser, AA ^{[1
]}

机构：

[1] Clin Bone Marrow Transplantat & Hematol Oncol, D-55743 Idar Oberstein, Germany

来源：

BONE MARROW TRANSPLANTATION | 2000年 / 25卷 / Suppl 2期

关键词：

mycophenolate mofetil; GVHD; hemopoietic stem cell transplantation;

D O I：

10.1038/sj.bmt.1702345

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

GVHD continues to be a major complication after allogeneic hematopoietic stem cell transplantation even when the recipient is given immunosuppression for the prophylaxis of this severe disease. There have been many advances in the prevention and treatment of GVHD, using compounds such as cyclosporine, FK506, mycophenolate mofetil or monoclonal IL-2 receptor antagonist. New strategies seem to include sequential therapy involving the blocking of both endogenous cytokines and alloreactive donor cells. However, further clinical and laboratory studies are needed in order to improve the therapy of established GVHD.

引用

页码：S12 / S15

页数：4

共 28 条

[11]

HERVE P, 1990, BLOOD, V75, P1017

[12] RESPONSE OF STEROID-RESISTANT GRAFT-VERSUS-HOST DISEASE TO LYMPHOBLAST ANTIBODY CBL1 [J].

HESLOP, HE ;

BENAIM, E ;

BRENNER, MK ;

KRANCE, RA ;

STRICKLIN, LM ;

ROCHESTER, RJ ;

BILLING, R .

LANCET, 1995, 346 (8978) :805-806

[13] Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invariant chain peptide [J].

Hess, AD ;

Bright, EC ;

Thoburn, C ;

Vogelsang, GB ;

Jones, RJ ;

Kennedy, MJ .

BLOOD, 1997, 89 (06) :2203-2209

[14]

Kummer G, 1999, BONE MARROW TRANSPL, V23, pS94

[15] Treatment of chronic graft-versus-host disease with clofazimine [J].

Lee, BSJ ;

Wegner, SA ;

McGarigle, CJ ;

Bierer, BE ;

Antin, JH .

BLOOD, 1997, 89 (07) :2298-2302

[16] A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease [J].

McCarthy, PL ;

Williams, L ;

HarrisBacile, M ;

Yen, J ;

Przepiorka, D ;

Ippoliti, C ;

Champlin, R ;

Fay, J ;

Blosch, C ;

Jacobs, C ;

Anasetti, C .

TRANSPLANTATION, 1996, 62 (05) :626-631

[17]

MOSMANN TR, 1986, J IMMUNOL, V136, P2348

[18] THE OUTCOME OF MATCHED UNRELATED DONOR BONE-MARROW TRANSPLANTATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING MOLECULAR TYPING FOR DONOR SELECTION AND GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS REGIMEN OF CYCLOSPORINE, METHOTREXATE, AND PREDNISONE [J].

NADEMANEE, A ;

SCHMIDT, GM ;

PARKER, P ;

DAGIS, AC ;

STEIN, A ;

SNYDER, DS ;

ODONNELL, M ;

SMITH, EP ;

STEPAN, DE ;

MOLINA, A ;

WONG, KK ;

MARGOLIN, K ;

SOMLO, G ;

LITTRELL, B ;

WOO, D ;

SNIECINSKI, I ;

NILAND, JC ;

FORMAN, SJ .

BLOOD, 1995, 86 (03) :1228-1234

[19] FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors [J].

Nash, RA ;

Pineiro, LA ;

Storb, R ;

Deeg, HJ ;

Fitzsimmons, WE ;

Furlong, T ;

Hansen, JA ;

Gooley, T ;

Maher, RM ;

Martin, P ;

McSweeney, PA ;

Sullivan, KM ;

Anasetti, C ;

Fay, JW .

BLOOD, 1996, 88 (09) :3634-3641

[20] THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE [J].

PARKER, PM ;

CHAO, N ;

NADEMANEE, A ;

ODONNELL, MR ;

SCHMIDT, GM ;

SNYDER, DS ;

STEIN, AS ;

SMITH, EP ;

MOLINA, A ;

STEPAN, DE ;

KASHYAP, A ;

PLANAS, I ;

SPIELBERGER, R ;

SOMLO, G ;

MARGOLIN, K ;

ZWINGENBERGER, K ;

WILSMAN, K ;

NEGRIN, RS ;

LONG, GD ;

NILAND, JC ;

BLUME, KG ;

FORMAN, SJ .

BLOOD, 1995, 86 (09) :3604-3609

← 1 2 3 →